Everest Medicines' EVER001 demonstrated an 81.8% overall clinical remission rate in the low-dose cohort and 85.7% in the high-dose cohort for pMN patients.
NEFECON®, Everest Medicines' etiological treatment for IgA nephropathy (IgAN), has been included in China's National Reimbursement Drug List (NRDL), effective January 1, 2025.